WHO policy development processes for a new vaccine: Case study of malaria vaccines

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Milstien, Julie ^a   Crdenas, Vicky ^b   Cheyne, James ^c   Brooks, Alan ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b PATH Malaria Vaccine Initiative   (United States)

^c PATH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MALARIA VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; PYRIMETHAMINE PLUS SULPHADOXINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL TRIAL; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVELOPING COUNTRY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INFANCY; MALARIA; MALARIA CONTROL; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PROFESSIONAL PRACTICE; ROTAVIRUS INFECTION; STEVENS JOHNSON SYNDROME; UTERINE CERVIX CANCER; VACCINATION; WORLD HEALTH ORGANIZATION; COST; ECONOMICS; HEALTH; MANAGEMENT;

COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; HEALTH POLICY; HUMANS; MALARIA; MALARIA VACCINES; POLICY MAKING; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 77954884526     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-182     Document Type: Article

References (50)

1. Efficacy of the RTS,S/AS02A malaria vaccine against Plasmodium falciparum infection and disease in young African children: randomized control trial. PL Alonso J Sacarlal JJ Aponte A Leach E Macete J Milman I Mandomando B Spiessens C Guinovart M Espasa Q Bassat P Aide O Ofori-Anyinam MM Navia S Corachan M Ceuppens MC Dubois MA Demoitié F Dubovsky C Menéndez N Tornieporth WR Ballou R Thompson J Cohen, Lancet 2004 364 1411 1420 10.1016/S0140-6736(04) 17223-1 15488216
2. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized control trial. PL Alonso J Sacarlal JJ Aponte A Leach E Macete P Aide B Sigauque J Milman I Mandomando Q Bassat C Guinovart M Espasa S Corachan M Lievens MM Navia MC Dubois C Menendez F Dubovsky J Cohen R Thompson WR Ballou, Lancet 2005 366 2012 2018 10.1016/S0140-6736(05)67669-6 16338450
3. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. P Bejon J Lusingu A Olotu A Leach M Lievens J Vekemans S Mshamu T Lang J Gould MC Dubois MA Demoitié JF Stallaert P Vansadia T Carter P Njuguna KO Awuondo A Malabeja O Abdul S Gesase N Mturi CJ Drakeley B Savarese T Villafana WR Ballou J Cohen EM Riley MM Lemnge K Marsh L von Seidlein, N Engl J Med 2008 359 2521 2532 10.1056/NEJMoa0807381 19064627
4. Safety and immunogenicity of RTS,S/AS02 malaria vaccine in infants. S Abdulla R Oberholzer O Juma S Kubhoja F Machera C Membi S Omari A Urassa H Mshinda A Jumanne N Salim M Shomari T Aebi DM Schellenberg T Carter T Villafana MA Demoitié MC Dubois A Leach M Lievens J Vekemans J Cohen WR Ballou M Tanner, N Engl J Med 2008 359 2533 2544 10.1056/NEJMoa0807773 19064623
5. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. A Liberati DG Altman J Tetzlaff C Mulrow PC Gøtzsche JP Ioannidis M Clarke PJ Devereaux J Kleijnen D Moher, PLoS Med 2009 6 1000100 Epub 2009 Jul 21 10.1371/journal.pmed.1000100 19621070
6. Global Malaria Programme. http://www.who.int/malaria
7. Immunization Vaccines and Biologicals. http://www.who.int/immunization/en
8. Strategic Advisory Group of Experts. http://www.who.int/immunization/ sage/en/index.html
9. Recommandations et politiques vaccinales mondiales. Le rle de l'OMS. P Duclos J-M Okwo-Bele, Med Sci (Paris) 2007 23 409 416 17433232
10. Global Programme on Evidence for Health Policy. Guidelines for WHO Guidelines Geneva: World Health Organization 2003 EIP/GPE/EQC/2003.1
11. Use of evidence in WHO recommendations. AD Oxman JN Lewis A Fetheim, Lancet 2007 369 1883 1889 10.1016/S0140-6736(07)60675-8 17493676
12. Leading by example, a culture change at WHO. Comment. S Hill T Pang, Lancet 2007 369 1842 1844 10.1016/S0140-6736(07)60676-X 17493675
13. The WHO Position Paper on Haemophilus influenzae type b conjugate vaccines. Global Programme for Vaccines and Immunization, Wkly Epidemiol Rec 1998 73 64 68 9542461
14. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. J Eskola H Peltola AK Takala H Käyhty M Hakulinen V Karanko E Kela P Rekola PR Rönnberg JS Samuelson, N Engl J Med 1987 317 717 722 3306379
15. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. SB Black HR Shinefield B Fireman R Hiatt M Polen E Vittinghoff, Pediatr Infect Dis J 1991 10 97 104 10.1097/00006454-199102000-00004 2062621
16. Recommendations from the Strategic Advisory Group of Experts to the Department of Immunization, Vaccines and Biologicals. World Health Organization, Wkly Epidemiol Rec 2004 79 43 52 14974354
17. Conclusions and recommendations from the Strategic Advisory Group of Experts to the Department of Immunization, Vaccines and Biologicals. World Health Organization, Wkly Epidemiol Rec 2006 81 1 12 16671245
18. World Health Organization, http://www.who.int/nuvi/hib/vu-hib5.pdf
19. Hib Initiative. http://www.hibaction.org
20. Pneumococcal vaccines - WHO position paper. World Health Organization, Wkly Epidemiol Rec 2003 78 110 119
21. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. KP Klugman SA Madhi RE Huebner R Kohberger N Mbelle N Pierce Vaccine Trialists Group, N Engl J Med 2003 349 1341 1348 10.1056/NEJMoa035060 14523142
22. Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double-blind, placebo-controlled trial. FT Cutts SM Zaman G Enwere S Jaffar OS Levine JB Okoko C Oluwalana A Vaughan SK Obaro A Leach KP McAdam E Biney M Saaka U Onwuchekwa F Yallop NF Pierce BM Greenwood RA Adegbola Gambian Pneumococcal Vaccine Trial Group, Lancet 2005 365 1139 1146 10.1016/S0140-6736(05)71876-6 15794968 (Pubitemid 40417563)
23. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States 1998-2003. Centers for Disease Control and Prevention (CDC), Morb Mortal Wkly Rep 2005 54 893 897
24. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. A Sinha O Levine MD Knoll F Muhib TA Lieu, Lancet 2007 369 389 396 10.1016/S0140-6736(07) 60195-0 17276779
25. Meeting of the immunization Strategic Advisory Group of Experts, November 2006 - conclusions and recommendations. World Health Organization, Wkly Epidemiol Rec 2007 82 1 16 17219693
26. Pneumo Alert: Rwanda becomes first GAVI-eligible nation to introduce vaccines for world's leading infectious child killer. http://www.preventpneumo. org
27. Worldwide progress in introducing pneumococcal conjugate vaccines 2000-2008. World Health Organization, Wkly Epidemiol Rec 2008 83 388 392 18949860
28. Rotavirus vaccines. WHO Position paper. World Health Organization, Wkly Epidemiol Rec 1999 74 33 40 10023196
29. World Health Organization, Report of the meeting on future directions for rotavirus vaccine research in developing countries. Geneva 2000 (WHO/V&B/00.23)
30. Recommendations from the Strategic Advisory Group of Experts to the Department of Immunization, Vaccines and Biologicals. World Health Organization, Wkly Epidemiol Rec 2005 80 15 16
31. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. PM Heaton MG Goveia JM Miller P Offit HF Clark, J Infect Dis 2005 192 Suppl 1 17 21 10.1086/431500 16088800
32. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. B De Vos T Vesikari AC Linhares B Salinas I Pérez-Schael GM Ruiz-Palacios L Guerrero Mde KB Phua A Delem K Hardt, Pediatr Infect Dis J 2004 23 10 Suppl 179 82 15502699
33. Enhanced Diarrheal Disease Control Resource Center. http://www. eddcontrol.org
34. Meeting of the immunization Strategic Advisory Group of Experts, November 2008 - conclusions and recommendations. World Health Organization, Wkly Epidemiol Rec 2009 84 1 16 19149014
35. Presentation - Update and Future Directions for the Global Alliance for Vaccines and Immunization. Kumar Ranjana, http://www.rotavirusvaccine.org/index. htm
36. Nicaraguan Vaccination Program. http://www.merck.com/responsibility/ access/access-feature-nicaraguan.html
37. Quadrivalent Human Papilloma Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC), Morb Mortal Wkly Rep 2007 56 RR02 1 24
38. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised placebo-controlled trial. D Schellenberg C Menendez E Kahigwa J Aponte J Vidal M Tanner H Mshinda P Alonso, Lancet 2001 357 1471 1477 10.1016/S0140-6736(00)04643-2 11377597
39. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. D Schellenberg C Menendez E Kahigwa J Aponte J Vidal M Tanner H Mshinda P Alonso, Lancet 2003 361 1853 1860 10.1016/S0140-6736(03)12515-9 12788572
40. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. D Schellenberg C Menendez JJ Aponte E Kahigwa M Tanner H Mshinda P Alonso, Lancet 2005 365 1481 1483 10.1016/S0140-6736(05)66418-5 15850632
41. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. D Chandramohan S Owusu-Agyei I Carneiro T Awine K Amponsa-Achiano N Mensah S Jaffar R Baiden A Hodgson F Binka B Greenwood, BMJ 2005 331 727 733 10.1136/bmj.331.7519.727 16195288
42. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. E Macete P Aide JJ Aponte S Sanz I Mandomando M Espasa B Sigauque C Dobão S Mabunda M DgeDge P Alonso C Menendez, J Infect Dis 2006 194 276 285 10.1086/505431 16826474
43. IPTi Consortium. http://www.ipti-malaria.org
44. World Health Organization, Report of Technical Consultation on Intermittent Preventive Treatment for Malaria in Infancy (IPTi) Global Malaria Programme, World Health Organization, Geneva 2006 25 27
45. Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? D Chandramohan J Webster L Smith T Awine S Owusu-Agyei I Carneiro, Trop Med Int Health 2007 12 743 50 17550471
46. A randomized control trial of extended intermittent preventive antimalarial treatment in infants. R Kobbe C Kreuzberg S Adjei B Thompson I Langefeld PA Thompson HH Abruquah B Kreuels M Ayim W Busch F Marks K Amoah E Opoku CG Meyer O Adjei J May, Clin Infect Dis 2007 45 16 25 10.1086/518575 17554695
47. Intermittent preventive antimalarial treatment in infancy. WHO IPTi Technical Expert Group, Lancet 2008 372 1383 1384 18940461
48. Assessment of the role of intermittent preventive treatment for malaria in infants. Committee on the Perspectives on the Role of Intermittent Preventive Treatment for Malaria in Infants, ISBN: 0-309-11909-X 2008
49. World Health Organization, Report of the Technical Consultation on Intermittent Preventive Treatment in infants (IPTi). Geneva 2009
50. World Health Organization, Report of the First Meeting of the Malaria Vaccine Advisory Committee (MALVAC). Geneva 2003